<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1526">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05141292</url>
  </required_header>
  <id_info>
    <org_study_id>BIOMS-MVD</org_study_id>
    <nct_id>NCT05141292</nct_id>
  </id_info>
  <brief_title>A Registry Study of Biomarkers in Mitral Valve Disease (BIOMS-MVD)</brief_title>
  <official_title>A Registry Study of Biomarkers in Mitral Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Institute of Heart, Lung and Blood Vessel Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Institute of Heart, Lung and Blood Vessel Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry study aims to discover the prognostic value of bio-markers in mitral valve&#xD;
      disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the prognostic value of biomarkers in mitral&#xD;
      valve disease.Patients with confirmed diagnosis of mitral valve disease are enrolled.The&#xD;
      primary outcome is all-cause mortality based on the death certificates. The secondary outcome&#xD;
      is readmission for heart failure and all-cause mortality/readmission for heart failure&#xD;
      according to the patients' medical records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of death (all cause)</measure>
    <time_frame>1 years of follow-up</time_frame>
    <description>Number of death within 2 years of discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of rehospitalizations</measure>
    <time_frame>1 years of follow-up</time_frame>
    <description>Number of heart failure related hospitalization within 1 years of discharge</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heart failure accorrding to Inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients clinically diagnosed with mitral valve disease in Beijing Anzhen Hospital&#xD;
             from April 2016 to December 2019&#xD;
&#xD;
          -  The operator performs more than 25 mitral valve operations per year / the operator&#xD;
             unit has surgeons who complete 50 operations per year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age â‰¤ 18 years&#xD;
&#xD;
          -  Failure to obtain medical records and ultrasound data&#xD;
&#xD;
          -  Refuse follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jie Du</last_name>
    <role>Study Director</role>
    <affiliation>The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan Wang, Dr</last_name>
    <phone>13910161443</phone>
    <email>wangyuan980510@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ning Zhou, Dr</last_name>
    <phone>18611179515</phone>
    <email>drzhou9515@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan WANG, PhD</last_name>
      <phone>86-010-64456169</phone>
      <email>wangyuan980510@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

